

| | | | |
|--|--|-------------------------------|--------------------------|
| Form PTO-1449 | U.S. Department of Commerce Patent and Trademark Office | ATTY. DOCKET NO. PB60432 | SERIAL NO. 10/567,803 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i> | | APPLICANT Coles, et al. | |
| | | FILING DATE March 31, 2008 | GROUP 1615 |

U.S. PATENT DOCUMENTS

| Examiner Initial | | Document Number | Date | Name | Class | Subclass | Filing Date If Appropriate |
|------------------|--|-----------------|------|------|-------|----------|----------------------------|
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

FOREIGN PATENT DOCUMENTS

| | Document Number | Date | Country | Class | Subclass | Translation Yes | No |
|--|-----------------|------|---------|-------|----------|--------------------|----|
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

| | |
|--|---|
| | Bristol-Myers Squibb Company. Glucophage® (metformin hydrochloride tablets) and Glucophage® XR (metformin hydrochloride extended-release tablets). NDA 20-357/S-031 and NDA 21-202/S-016. Pages 3-32. |
| | |
| | |
| | |
| | |
| | |
| | |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

n:\cls\cases\pb60432\pb60432_us_supp_pto1449_10567803.doc